お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:がん免疫診断 - COVID-19の影響と更新に基づくがん免疫診断市場予測: 2021年~2025年の予測および分析
市場調査レポート
商品コード
987593

がん免疫診断 - COVID-19の影響と更新に基づくがん免疫診断市場予測: 2021年~2025年の予測および分析

Immuno-Oncology Diagnostics Market Forecasts for Immuno-Oncology Diagnostics with COVID-19 Impact and Updates. Including Executive/Consultant Guides and Customized Forecasting/Analysis. 2021 to 2025

出版日: | 発行: Howe Sound Research | ページ情報: 英文 263 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.00円
がん免疫診断 - COVID-19の影響と更新に基づくがん免疫診断市場予測: 2021年~2025年の予測および分析
出版日: 2021年02月04日
発行: Howe Sound Research
ページ情報: 英文 263 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

現在、がん治療の革命が進められています。体の自然な免疫防御の利用に基づく新しい治療法は、前例のない成功を収めています。しかしながら、適切な治療法を選択するためには、診断、特にバイオマーカーが切実に必要であると考えられています。

当レポートは、世界のがん免疫診断市場について調査しており、市場の定義、技術ガイド、市場動向、成長および抑制要因、最近の開発、アッセイタイプ・地域別の市場分析、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

  • マーケットガイド
  • COVID-19パンデミックの状況分析と影響
  • エグゼクティブおよびマーケティングスタッフのためのガイド
  • 投資アナリストおよび経営コンサルタントのためのガイド

第1章 イントロダクションと市場の定義

  • がん免疫診断とは何か
  • がん免疫:迫り来る治療法
    • 主導的な役割を果たすがん免疫診断
  • 市場の定義
  • 調査手法
  • 米国の医療市場と臨床検査:展望
    • 臨床検査のための米国のメディケア支出

第2章 免疫療法:免疫技術のガイド

  • 免疫システム
    • 自然免疫システム
    • 適応免疫システム
    • 免疫監視システム
  • がん免疫診断
    • チェックポイントアッセイ
    • サイトカインアッセイ
    • ゲノム生殖細胞系列
    • ゲノム腫瘍
    • 腫瘍微小環境
    • その他

第3章 業界の概要

  • 市場企業の動向
    • 学術調査室
    • 診断テスト開発者
    • ゲノム計装サプライヤー
    • 医薬品/試薬サプライヤー
    • 独立したテストラボ
    • 公立国立/地域研究所
    • 病院ラボ
    • 医師ラボ
    • 監査機関
    • 認証機関

第4章 市場動向

  • 成長要因
    • 結果の可能性
    • コンパニオン診断
    • 資金調達
    • テクノロジー環境
    • ターゲットソリューション
  • 抑制要因
    • 診断の複雑な役割
    • 臨床試験の役割
    • プロトコル
  • 診断技術の開発
    • 組み合わせ:問題と複雑さ
    • 診断の役割の変化
    • 多重化とFoundationOne
    • ディスラプションダイナミック
    • バイオマーカーの競争
    • 今後の5年間の見通し

第5章 がん免疫診断:最近の進展

  • 最近の開発
    • OncoDNA:HalioDxを使用による北米への拡大
    • Adaptive Biotechnologies:第2四半期、ソリューションのImmunoSeqの契約に署名
    • Qiagen:がん免疫ポートフォリオの拡大
    • COVID-19と戦うためにリダイレクトされた免疫プロファイリングシステム
    • IncellDx:PD-L1検出特許を取得
    • FDA:トラスツズマブのCDxを承認
    • ArcherDx:がん免疫のためのアストラゼネカとの提携
    • Agilent PD-L1アッセイ:FDAの承認を取得
    • BiocareMedical:7つの新しいIVD抗体を発表、など

第6章 主要な免疫療法企業のプロファイル

  • 10X Genomics
  • Abbott Laboratories
  • Abcam
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience
  • Angle plc
  • Apocell
  • ARUP Laboratories
  • Beckman Coulter
  • Becton Dickinson
  • Bioarray Genetics
  • BioCartis
  • Biocept
  • Biodesix Inc
  • BioFluidica
  • BioGenex
  • bioMírieux
  • Bio-Rad
  • Bio-Techne
  • Bristol-Myers Squibb
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Charles River Laboratories
  • Chronix Biomedical
  • Circulogene
  • Clearbridge BioMedics
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Dako (Agilent)
  • Diagnologix LLC
  • Epic Sciences
  • Exosome Diagnostics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine
  • Freenome
  • Genomic Health
  • GenomOncology
  • GRAIL
  • Guardant Health
  • HalioDx
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invivoscribe
  • Leica Biosystems
  • Luminex
  • MDx Health
  • Merck & Co., Inc
  • MIODx
  • Molecular MD
  • MRM Proteomics Inc
  • Myriad Genetics/Myriad RBM
  • Nanostring
  • Natera
  • Neogenomics
  • New Oncology
  • Oncocyte
  • Ortho Clinical Diagnostics
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Pfizer
  • Promega
  • Protagen Diagnostics
  • Qiagen
  • Quanterix
  • Rarecells SAS
  • Roche Diagnostics
  • Siemens
  • Silicon Biosystems
  • SkylineDx
  • SRI International
  • Sysmex
  • Thermo Fisher
  • Trovagene
  • Vortex Biosciences

第7章 がん免疫診断の世界市場

  • 国別の世界の市場概要
    • チャート
  • アッセイタイプ別の世界の市場:概要

第8章 世界市場:アッセイタイプ別

  • チェックポイント
  • サイトカイン
  • 生殖細胞系遺伝学
  • 遺伝的腫瘍
  • 腫瘍微小環境
  • その他

第9章 付録

  • 年別:FDAがん治療薬の承認
  • 2010年から2016年に開始された臨床試験
  • がん治療の有病率
図表

Table of Tables

  • Table 1 List of Cancers by Mortality
  • Table 2 Lab Spending 2014 to 2024
  • Table 3 Overview of Innate and Adaptive Immunity
  • Table 4 FDA Approved Monoclonal Antibodies in Cancer treatment
  • Table 5 FDA Approved Companion diagnostics in Cancer treatment
  • Table 6 Market Players by Type
  • Table 7 Five Factors Driving Growth
  • Table 8 Three Factors Limiting Growth
  • Table 9 - Global Market by Region
  • Table 10 Global Market by Assay Type
  • Table 11 Checkpoint by Country
  • Table 12 Cytokine by Country
  • Table 13 Germline Genetic by Country
  • Table 14 Genetic Tumor by Country
  • Table 15 Tumor Microenvironment by Country
  • Table 16 Other by Country

Table of Figures

  • Figure 1 Cancer Death Rates - USA, CDC
  • Figure 2 Clinical Lab Spending 2014 to 2024
  • Figure 3 Helper T Cell Roles
  • Figure 4 Antibody Diagram
  • Figure 5 Macrophages attack a Cancer Cell
  • Figure 6 The Tumour Micro Environment
  • Figure 7 Comparing IO Diagnostic and Traditional Testing
  • Figure 8 Growth rates of IO DiagnosticTechnologies
  • Figure 9 Global Market Density Chart
  • Figure 10 Global Market by Assay Type - Base vs. Final
  • Figure 11 Global Market by Assay Type Base Year
  • Figure 12 Global Market by Assay Type End Year
  • Figure 13 Assay Type Share by Year
  • Figure 14 Assay Type Segments Growth
  • Figure 15 Checkpoint Growth
  • Figure 16 Cytokine Growth
  • Figure 17 Germline Genetic Growth
  • Figure 18 Genetic Tumor Growth
  • Figure 19 Tumor Microenvironment Growth
  • Figure 20 Other Growth
  • Figure 21 FDA Cancer Drug Approvals by Year
  • Figure 22 Clinical Trials for Immunotherapy by Year
  • Figure 23 Pie Chart of Prevalence of Cancer Treatments
目次

OVERVIEW:

Revolution in cancer therapy to be driven by new diagnostics. Histology, genomics and liquid biopsy converge. COVID-19 changes the focus of research.

This is a complex area but this readable report will bring the entire management team up to speed, on both the technology and the opportunity and the surprising impact of COVID-19 on what might seem to be an unrelated area.

A revolution in cancer therapy is underway. New therapy based on using the body's natural immune defenses is having unprecedented success. But diagnostics, especially biomarkers are desperately needed to help select the right therapy.

The technology is moving faster than the market. The impact on the health care industry is enormous. Tumor Mutational Burden? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

  • i. Market Guides
  • i. Situation Analysis & Impact of COVID-19 Pandemic
  • ii. Guide for Executives and Marketing Staff
  • iii. Guide for Investment Analysts and Management Consultants

1. Introduction and Market Definition

  • 1.1 What are Immuno-Oncology Diagnostics?
  • 1.2 Immuno-oncology - the looming cure
    • 1.2.1 Immuno-oncology Diagnostics Takes a Leading Role
  • 1.3 Market Definition
    • 1.3.1 Market Size
    • 1.3.2 Currency
    • 1.3.3 Years
  • 1.4 Methodology
    • 1.4.1 Authors
    • 1.4.2 Sources
  • 1.5 U.S. Medical Market and laboratory Testing - Perspective
    • 1.5.1 U.S. Medicare Expenditures for Laboratory Testing

2. Immunotherapy - Guide to Immune Technologies

  • 2.0 The Immune System
    • 2.0.1 Innate immune system
      • 2.0.1.1 Surface barriers
      • 2.0.1.2 Inflammation
      • 2.0.1.3 Complement system
      • 2.0.1.4 Cellular barriers
      • 2.0.1.5 Natural killer cells
    • 2.0.2 Adaptive immune system
      • 2.0.2.1 Lymphocytes
      • 2.0.2.2 Killer T cells
      • 2.0.2.3 Helper T cells
      • 2.0.2.4 Gamma delta T cells
      • 2.0.2.5 B lymphocytes and antibodies
    • 2.0.3 Tumor immunology - the immune surveillance system
  • 2.1 Immuno Oncology Diagnostics
    • 2.1.1 Checkpoint Assays
      • 2.1.1.1 Outlook for Checkpoint Assays
    • 2.1.2 Cytokine Assays
      • 2.1.2.1 Outlook for Cytokine Assays
    • 2.1.3 Genomic Germline
      • 2.1.3.1 Outlook for Genomic Germline
    • 2.1.4 Genomic Tumour
      • 2.1.4.1 Outlook for Genomic Tumour
    • 2.1.5 Tumor Microenviroment
      • 2.1.5.1 Outlook for Tumor Micro Environment
    • 2.1.6 Others
      • 2.1.6.1 Outlook for Other Diagnostics

3. Industry Overview

  • 3.1 Players in a Dynamic Market
    • 3.1.1 Academic Research Lab
    • 3.1.2 Diagnostic Test Developer
    • 3.1.3 Genomic Instrumentation Supplier
      • 3.1.3.1 Cell Separation and Viewing Instrumentation Supplier
    • 3.1.4 Pharmaceutical/Reagent Supplier
    • 3.1.5 Independent Testing Lab
    • 3.1.6 Public National/regional lab
    • 3.1.7 Hospital lab
    • 3.1.8 Physician Lab
    • 3.1.9 Audit Body
    • 3.1.10 Certification Body

4. Market Trends

  • 4.1 Factors Driving Growth
    • 4.1.1 Outcome potential
    • 4.1.2 Companion Diagnostics
    • 4.1.3 Funding
    • 4.1.4 Technology Environment
    • 4.1.5 Target Solutions
  • 4.2 Factors Limiting Growth
    • 4.2.1 Complex Role of Diagnostics
    • 4.2.2 Clinical Trials Role
    • 4.2.3 Protocols
  • 4.3 Diagnostic Technology Development
    • 4.3.1 Combinations - Issues and Complexity
    • 4.3.2 Shifting Role of Diagnostics
    • 4.3.3 Multiplexing and Foundation One
    • 4.3.4 The Disruption Dynamic
    • 4.3.5 The Race for Biomarkers
    • 4.3.6 The Next Five Years

5. Cancer Immuno-Oncology Diagnostics Recent Developments

  • 5.1 Recent Developments - Importance and How to Use This Section
    • 5.1.1 Importance of These Developments
    • 5.1.2 How to Use This Section
      • OncoDNA use HalioDx to Expand into North America
      • Adaptive Biotechnologies, Q2 Solutions Sign Agreement for ImmunoSeq
      • Qiagen Expands Immuno-Oncology Portfolio
      • Immune Profiling System Redirected to Fight COVID-19
      • IncellDx Awarded PD-L1 Detection Patent
      • FDA Approves CDx for Trastuzumab
      • Promega Nabs CE Mark for Microsatellite Instability IVD
      • ArcherDx partners with AstraZeneca for Immuno-Oncology
      • Germline Results Guides Precision Therapy
      • Agilent PD-L1 Assay Gets FDA Approval
      • Bayer, OrigiMed Form Companion Diagnostic Development Alliance
      • Bio-Me to Develop Microbiome Biomarker Test for Cancer Immunotherapy
      • SkylineDx, BioInvent Collaborate to Characterize Predictive Immunological
      • Signatures
      • Biocare Medical Launches 7 Novel IVD Antibodies
      • Oncocyte to Acquire Insight Genetics for $12M
      • Novigenix and BioLizard to develop NGS Based Diagnostic Algorithm
      • Biodesix and Immodulon Collaborate for Pancreatic Cancer Treatment
      • Generex to Merge with NuGenerex Immuno-Oncology
      • Cellgen Diagnostics and Genomic Testing Cooperative Partner to Develop
      • Companion Diagnostics for Cancer Therapies
      • Hematogenix Launches FDA Approved Immuno-oncology Test for Triple-Negative
      • Breast Cancer
      • Icon Acquires MolecularMD
      • Guardant Health to Develop Companion Diagnostic Tests for AstraZeneca
      • Tumor Mutational Burden as Predictor of Immunotherapy Success

6. Profiles of Key Immunotherapy Companies

  • 10X Genomics
  • Abbott Laboratories
  • Abcam
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience
  • Angle plc
  • Apocell
  • ARUP Laboratories
  • Beckman Coulter
  • Becton Dickinson
  • Bioarray Genetics
  • BioCartis
  • Biocept
  • Biodesix Inc
  • BioFluidica
  • BioGenex
  • bioMírieux
  • Bio-Rad
  • Bio-Techne
  • Bristol-Myers Squibb
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Charles River Laboratories
  • Chronix Biomedical
  • Circulogene
  • Clearbridge BioMedics
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Dako (Agilent)
  • Diagnologix LLC
  • Epic Sciences
  • Exosome Diagnostics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine
  • Freenome
  • Genomic Health
  • GenomOncology
  • GRAIL
  • Guardant Health
  • HalioDx
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invivoscribe
  • Leica Biosystems
  • Luminex
  • MDx Health
  • Merck & Co., Inc
  • MIODx
  • Molecular MD
  • MRM Proteomics Inc
  • Myriad Genetics/Myriad RBM
  • Nanostring
  • Natera
  • Neogenomics
  • New Oncology
  • Oncocyte
  • Ortho Clinical Diagnostics
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Pfizer
  • Promega
  • Protagen Diagnostics
  • Qiagen
  • Quanterix
  • Rarecells SAS
  • Roche Diagnostics
  • Siemens
  • Silicon Biosystems
  • SkylineDx
  • SRI International
  • Sysmex
  • Thermo Fisher
  • Trovagene
  • Vortex Biosciences

7. The Global Market for Immuno-Oncology Diagnostics

  • 7.1 Global Market Overview by Country
    • 7.1.1 Table - Global Market by Country
    • 7.1.2 Chart - Global Market by Country
  • 7.2 Global Market by Assay Type - Overview
    • 7.2.1 Table - Global Market by Assay Type
    • 7.2.2 Chart - Global Market by Assay Type - Base/Final Year Comparison
    • 7.2.3 Chart - Global Market by Assay Type - Base Year
    • 7.2.4 Chart - Global Market by Assay Type - End Year
    • 7.2.5 Chart - Global Market by Assay Type - Share by Year
    • 7.2.6 Chart - Global Market by Assay Type - Segments Growth

8. Global Immuno-Oncology Diagnostic Markets - By Assay Type

  • 8.1 Checkpoint
    • 8.1.1 Table Checkpoint - by Country
    • 8.1.2 Chart - Checkpoint Growth
  • 8.2 Cytokine
    • 8.2.1 Table Cytokine - by Country
    • 8.2.2 Chart - Cytokine Growth
  • 8.3 Germline Genetic
    • 8.3.1 Table Germline Genetic - by Country
    • 8.3.2 Chart - Germline Genetic Growth
  • 8.4 Genetic Tumor
    • 8.4.1 Table Genetic Tumor - by Country
    • 8.4.2 Chart - Genetic Tumor Growth
  • 8.5 Tumor Microenvironment
    • 8.5.1 Table Tumor Microenvironment - by Country
    • 8.5.2 Chart - Tumor Microenvironment Growth
  • 8.6 Other
    • 8.6.1 Table Other - by Country
    • 8.6.2 Chart - Other Growth

9. Appendices

  • 9.1 FDA Cancer Drug Approvals by Year
  • 9.2 Clinical Trials Started 2010 to 2016
  • 9.3 Prevalence of Cancer Treatments
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.